Rafferty Asset Management
AIMT

Rafferty Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Rafferty Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-46,846
Closed -$1.61M – 1073
2020
Q3 		$1.61M Sell
46,846
-3,413
-7% -$72.7K 0.02% 478
2020
Q2 		$840K Buy
+50,259
New +$853K 0.01% 595
2020
Q1 		– Sell
-68,577
Closed -$2.29M – 882
2019
Q4 		$2.29M Sell
68,577
-13,982
-17% -$391K 0.04% 343
2019
Q3 		$1.73M Sell
82,559
-12,242
-13% -$250K 0.03% 427
2019
Q2 		$1.97M Buy
94,801
+1,831
+2% +$37.7K 0.03% 421
2019
Q1 		$2.08M Buy
+92,970
New +$2.19M 0.03% 373

Rafferty Asset Management's AIMT Position: Q4 2020 in Review

Rafferty Asset Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 46,846 shares — an estimated $1.61M sold.

Rafferty Asset Management first reported a position in AIMT in Q1 2019 and held it in 6 quarters. The position peaked at $2.29M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Rafferty Asset Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Rafferty Asset Management sold 46,846 Aimmune Therapeutics shares in Q4 2020, an estimated $1.61M.
  • Rafferty Asset Management first reported a position in Aimmune Therapeutics in Q1 2019 and held it in 6 quarters.
  • Rafferty Asset Management's Aimmune Therapeutics position peaked at $2.29M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Rafferty Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.